Appili Therapeutics

About Appili Therapeutics

Appili Therapeutics is developing novel approaches to lead the fight against infectious disease. Despite numerous achievements in the development of anti-infectives, infectious disease remains the leading cause of death worldwide. Many pathogens are becoming increasingly resistant to standard anti-infectives, making treatment difficult or even impossible. The emergence and spread of deadly viruses and antimicrobial resistant bacteria and parasites remain critical threats to human health.
YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Kevin Sullivan, MBA
CFO: Kimberly Stephens
VP, Drug Development: Jamie Doran MSc, DABT, ERT
VP, Business Development: Sean McBride
PIPELINE:
Please click here for Appili Therapeutics' pipeline.